



## PRESS RELEASE

### DSM and Crucell Announce PER.C6<sup>®</sup> Technology Milestone

**Leiden, The Netherlands/Parsippany, USA, 11 March 2008** - DSM Biologics, a business unit of DSM Pharmaceutical Products, and Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) announced today that another important milestone has been achieved with the PER.C6<sup>®</sup> technology platform for the production of monoclonal antibodies and recombinant proteins. Scientists working at PERCIVIA reached a record level titer of 15 g/L at harvest for an antibody product. PERCIVIA is the PER.C6<sup>®</sup> Development Center joint venture between DSM and Crucell, located in Cambridge, Massachusetts, USA.

Marco Cacciuttolo, CEO of PERCIVIA comments, "This high titer achievement for PER.C6<sup>®</sup>, the highest reported to date, marks a major event for the biopharmaceutical industry. It demonstrates the power and robustness of the PER.C6<sup>®</sup> manufacturing platform and it clearly shows that the PER.C6<sup>®</sup> manufacturing platform will have a major impact to the overall economics of manufacturing biopharmaceuticals. DSM and Crucell recognized the enormous potential of the PER.C6<sup>®</sup> technology when starting the PERCIVIA joint venture just over 1 year ago. The breakthrough results achieved in a single year reinforce the special properties and abilities of the PER.C6<sup>®</sup> manufacturing platform. Based on our scientific data today, we are confident that we will be able to drive productivity even further."

Marcel Lubben, VP of Marketing, Sales & Business Development at DSM Biologics added, "We are very enthusiastic about the new 15 g/L milestone for our licensees. The PER.C6<sup>®</sup> manufacturing platform has tremendous potential for the biotech industry to significantly reduce the cost-of-goods for monoclonal antibodies and recombinant proteins, resulting in more affordable therapeutic treatments for patients."

Martina Molsbergen, VP Business Development at Crucell, added "The PER.C6<sup>®</sup> platform can reduce the risk of supply limitations and potentially postpone major capital expenditure decision hurdles for drug development companies. The 15 g/L milestone is instrumental in the further market penetration of the PER.C6<sup>®</sup> technology."

#### **About PER.C6<sup>®</sup> Technology**

Crucell's PER.C6<sup>®</sup> technology platform has been developed for the large-scale manufacture of biopharmaceutical products such as recombinant proteins including monoclonal antibodies. Compared to conventional production technologies, the strengths of PER.C6<sup>®</sup> technology lie in its excellent safety profile, scalability and productivity under serum-free culture conditions.

#### **About Crucell**

Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) is a global biotechnology company focused on research, development, production and marketing of vaccines, proteins and antibodies that prevent and treat primarily



infectious diseases. Its vaccines are sold in public and private markets worldwide. Crucell's core portfolio includes a vaccine against hepatitis B, a fully-liquid vaccine against five important childhood diseases and a virosome-adjuvanted vaccine against influenza. Crucell also markets travel vaccines, such as the only oral anti-typhoid vaccine, an oral cholera vaccine and the only aluminum-free hepatitis A vaccine on the market. The Company has a broad development pipeline, with several product candidates based on its unique PER.C6<sup>®</sup> production technology. The Company licenses its PER.C6<sup>®</sup> technology and other technologies to the biopharmaceutical industry. Important partners and licensees include DSM Biologics, sanofi-aventis, Novartis, Wyeth and Merck & Co. Crucell is headquartered in Leiden, the Netherlands, with subsidiaries in Switzerland, Spain, Portugal, Italy, Sweden, Korea and the US. The Company employs over a 1000 people. For more information, please visit [www.crucell.com](http://www.crucell.com).

#### **About DSM Biologics**

DSM Biologics, a business unit of DSM Pharmaceutical Products, is a global provider of manufacturing technology & services to the biopharmaceutical industry. In addition to offering world-class biopharmaceutical manufacturing services, DSM Biologics has co-exclusive rights, along with Dutch biotech company Crucell N.V., to license the high-producing PER.C6<sup>®</sup> human cell line as a production platform for recombinant proteins and monoclonal antibodies. The combination of the PER.C6<sup>®</sup> human cell line and DSM's manufacturing services provides companies with a turn-key biologic manufacturing solution reducing cost, risk and time to market.

#### **DSM – the Life Sciences and Materials Sciences Company**

DSM creates innovative products and services in Life Sciences and Materials Sciences that contribute to the quality of life. DSM's products and services are used globally in a wide range of markets and applications, supporting a healthier, more sustainable and more enjoyable way of life. End markets include human and animal nutrition and health, personal care, pharmaceuticals, automotive, coatings and paint, electrics and electronics, life protection and housing. DSM has annual sales of almost EUR 8.8 billion and employs some 23,000 people worldwide. The company is headquartered in the Netherlands, with [locations](#) on five continents. DSM is listed on Euronext Amsterdam.

#### **For further information please contact:**

##### **DSM Pharmaceutical Products**

Karen King  
President  
DSM Biologics  
Tel: +1-973-257-8427  
[Karen.King@dsm.com](mailto:Karen.King@dsm.com)

##### **DSM Biologics**

Marcel Lubben  
Vice President  
Marketing, Sales & NBD  
Tel: +31-(0)46-477 3343  
[marcel-m.lubben@dsm.com](mailto:marcel-m.lubben@dsm.com)

##### **Crucell N.V. Media:**

Barbara Mulder  
Director Corporate Communications  
Tel: +31-(0)71-519 7346  
[press@crucell.com](mailto:press@crucell.com)

##### **Investors/Analysts:**

Oya Yavuz  
Director Investor Relations  
Tel: +31-(0)71-519 7064  
[ir@crucell.com](mailto:ir@crucell.com)



**Forward-looking statements**

*This press release contains forward-looking statements that involve inherent risks and uncertainties. These statements are based on current expectations, estimates and projections of the management of DSM and Crucell and information currently available to both companies. The statements involve certain risks and uncertainties that are difficult to predict and therefore DSM and Crucell do not guarantee that their expectations will be realized. Furthermore, DSM and Crucell have no obligation to update the statements contained in this press release.*

*Crucell has identified certain important factors that may cause actual results to differ materially from those contained in such forward-looking statements. For information relating to these factors please refer to the Form 20-F, as filed by Crucell with the U.S. Securities and Exchange Commission on June 13, 2007, and the section entitled "Risk Factors". Crucell prepares its financial statements under generally accepted accounting principles in the United States (US GAAP) and Europe (IFRS).*